0. Advocacy Graphic



The Voice of Addiction Medicine

 Leading the movement to transform America's addiction treatment infrastructure and expand access to research-validated, results-based care
ASAM_Seal_DarkBlue

ASAM's Advocacy Principles

Advocacy Webpage Graphics Teach It
TEACH addiction medicine by expanding and strengthening our workforce and dispelling stigma
Advocacy Webpage Graphics Standardize It
STANDARDIZE the delivery of addiction medicine so that more patients receive high-quality, evidence-based care
0. Advocacy Webpage Graphics Cover It
COVER addiction medicine in a way that expands patient access to coordinated, comprehensive care
 
Advocacy Homepage HR 6 Graphic
 




It's time we treat addiction like other chronic diseases 



workshop2

Advocacy Committees & Councils

ASAM's advocacy could not happen if not for the dedicated effort of our members.

0. Find a Policy Statement 1 - cropped

Public Policy Statements

Learn about ASAM's position on current policy issues.

Teamwork - smallest

Coalitions

ASAM is proud to work collaboratively with others to improve the lives of those living with addiction.
0. Advocacy Toolkits

Advocacy Toolkits

ASAM provides toolkits to help you advocate for public policies that advance addiction medicine and promote access to treatment


 
Legislative Tracker Graphic
 



newspapers-3488857_1920B

ASAM Joins the Friends of NIDA in Expressing Support for the Medical Marijuana Research Act

by | Jul 19, 2019

 

On July 17, Representatives Andy Harris (R-MD), Earl Blumenauer (D-OR), Zoe Lofgren (D-CA), H. Morgan Griffith (R-VA), Debbie Dingell (D-MI), and Rob Bishop (R-UT) introduced the Medical Marijuana Research Act of 2019, which would reduce many of the burdensome barriers researchers face when conducting legitimate scientific research involving cannabis. ASAM endorsed the bill in a letter from the Friends of NIDA. There is a growing body of research that indicates cannabis has the potential to effectively treat certain medical conditions. However, there is also significant evidence that consistent use of cannabis can have deleterious effects on a patient’s health. ASAM is pleased to endorse this bill, as it will serve to generate research that can better inform policymakers when legislating on this issue.

 

This bill would create an exception for cannabis from the current obstacles of Schedule I registration and review procedures. It would furthermore require that the Department of Justice approve applications from individuals seeking to manufacture or dispense cannabis for legitimate medical research unless such a registration is not in the public interest. Finally, the bill would require that the Department of Health and Human Services review existing medical and other research on cannabis and report the findings to Congress. Through these measures, the Medical Marijuana Research Act would streamline research efforts into cannabis while also better educating Congress on the current body of research pertaining to cannabis.  

 

Read the bill text here.

 

Read the Friends of NIDA Letter here.